Silence Therapeutics (Nasdaq:SLN) develops and delivers short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical needs. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters in Hammersmith, London.